Detail akcie Cue Biopharma Rg online

Business Summary: Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a novel class of injectable biologics designed to selectively engage and modulate tumor-specific T cells within the body to treat a broad range of cancers, chronic infectious diseases, and autoimmune diseases. The Company’s proprietary Immuno-STAT (Selective Targeting and Alteration of T Cells) platform harnesses the patient’s intrinsic immune repertoire to fully exploit its potential to fight cancer and restore health while avoiding the deleterious side effects of broad immune activation. The Company’s lead product candidate from the CUE-100 series, CUE-101, is a fusion protein biologic designed to target and activate antigen-specific T cells to fight HPV-driven cancers. Its second drug product candidate, CUE-102, targets Wilms’ Tumor 1 protein (WT-1), an oncofetal antigen. It is also developing CUE-103 and its Neo-STAT and RDI-STAT programs outside of oncology.
Financial Summary: BRIEF: For the nine months ended 30 September 2023, Cue Biopharma Inc revenues increased from $1.1M to $3.7M. Net loss decreased 3% to $37.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research and development - Balancing va decrease of 18% to $16.7M (expense), General and administrative - Balancing decrease of 42% to $4.7M (expense).